Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr Gordon on the FDA Approval of Liso-Cel in Relapsed/Refractory MCL

May 30th 2024

Leo I. Gordon, MD, discusses the significance of the FDA approval of liso-cel for patients with relapsed/refractory mantle cell lymphoma.

FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy

May 30th 2024

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCL

May 20th 2024

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

Dr Koff on Toxicities Associated With Pirtobrutinib in MCL

May 15th 2024

Jean L. Koff, MD, MS, discusses the toxicities associated with pirtobrutinib in the BRUIN trial for mantle cell lymphoma.

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS

May 14th 2024

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Efficacy and Safety of Pirtobrutinib Continue to Reshape MCL Treatment Paradigm

May 13th 2024

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL

May 2nd 2024

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCL

April 18th 2024

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

Zanubrutinib Associated With Longer Treatment Persistence, Duration, and TTD in Real-World MCL

April 17th 2024

Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.

B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL

April 17th 2024

B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.

Dr Pearse on the Utility of Pirtobrutinib in Relapsed/Refractory MCL

April 16th 2024

William B. Pearse, MD, discusses the current role of the BTK inhibitor pirtobrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr Coombs on Noncovalent BTK Inhibitors in Relapsed/Refractory MCL

April 5th 2024

Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCL

March 29th 2024

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL

March 29th 2024

CTL019 CAR T-cell therapy plus time-limited ibrutinib resulted in high complete response rates in relapsed/refractory mantle cell lymphoma.

Dr Phillips on Ongoing Research in High-Risk MCL

March 28th 2024

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

March 28th 2024

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma.

Dr Goy on Updated Data From ZUMA-2 With Brexu-Cel in MCL

March 27th 2024

Andre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.

Brexu-Cel Displays Superior Responses vs Pirtobrutinib in Relapsed/Refractory MCL Matching-Adjusted Indirect Comparison

March 22nd 2024

A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.

EZH2 Expression and TP53 Mutation Results in Inferior Outcomes in MCL

March 21st 2024

TP53 mutation and EZH2 expression negatively affect outcomes in mantle cell lymphoma, with a synergistic negative effect.

FDA Lifts Partial Clinical Hold on Trial Evaluating NX-2127 in R/R B-Cell Malignancies

March 11th 2024

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies